As the number of Covid-19 cases expand globally, every corner of the biotech industry will be impacted in some way. There will be office interruptions, delays in drug development and clinical trials, extensions of regulatory reviews, and limits on new drug launches. Sales of certain older drugs will drop along with prescriptions. Expect investor and financing challenges, too.
Why worry about Italy? So what if all the clincal trails in that country girnds to a halt? I am sure you know as well as I do that among the Big 5 EU nations as a drug market (UK, Germany, France, Spain and Italy), Italy with only barely 60 million people is a small fraction with insignificant revenue for any new drug and also for any existing drug sold in that country. So what if any new drug is NOT approved in Italy. Big deal. Patients in dire needs can always drive across the border to get it!
Comments are closed.